Abstract:Background: A malignant tumor's immune environment, including infiltrating immune cell status, can be critical to patient outcomes. Recent studies have shown that immune cell infiltration (ICI) in pancreatic cancer (PC) is highly correlated with the response to immunotherapy and patient prognosis. Therefore, we aimed to create an ICI score that accurately predicts patient outcomes and immunotherapeutic efficacy. Methods: The ICI statuses of patients with PC were estimated from the publicly available The Cancer Genome Atlas (TCGA) pancreatic ductal adenocarcinoma and GSE57495 gene expression datasets using two computational algorithms (CIBERSORT and ESTIMATE). ICI and transcriptome subsets were defined using a clustering algorithm, and survival analysis was also performed. Principal component analysis was used to calculate the novel ICI score, and gene set enrichment analysis was performed to identify the pathways underlying the defined clusters. The tumor mutational burden (TMB) was further explored in TCGA cohort, and survival analysis was used to assess the capability of the ICI and TMB scores to predict overall survival. Additionally, common driver gene mutations and their differential expression in the different ICI score group were investigated. Results: The ICI landscapes of 240 patients were generated using the devised algorithm, revealing three ICI and three gene clusters whose use improved the prediction of overall survival (p = 0.019 and p < 0.001, respectively). Crucial immune checkpoint genes were differentially expressed among these subtypes; the RIG-I-LIKE and NOD-LIKE receptor signaling pathways were enriched in samples with low ICI scores (p < 0.05). We also found that the TMB scores could predict survival outcomes, whereas the ICI scores also could predict prognoses independent of TMB. Notably, ICI scores could effectively predict responses to immunotherapy. KRAS, TP53, CDKN2A, SMAD4 and TTN remained the most commonly mutated genes in PC; moreover, KRAS and TP53 mutation rates were significantly different between the two ICI score groups. Conclusions: We developed a novel ICI score that could independently predict the response to immunotherapy and survival of patients with PC. Evaluation of the ICI landscape in a larger cohort could clarify the interactions between these infiltrating cells, the tumor microenvironment and response to immunotherapy. Lay abstract Pancreatic cancer (PC) is a lethal malignancy with a higher mortality rate. Currently, immunotherapy is increasingly interesting to clinical researchers and considered a novel and efficient treatment. However, in clinical practice, immunotherapy has not demonstrated consistent therapeutic responses across all patients. Thus, to identify the immunotherapy-sensitive subgroup of advanced PC patients is important based on immune cell infiltration. In this study, we downloaded and processed transcriptomic data from TCGA-PAAD and GEO databases and used CIBERSORT and ESTIMATE algorithms to reveal the immune cell infiltration landscape of pancreatic cancer. According to consensus clustering results, we identified three ICI and gene clusters for guiding the identification of immune-subtype in future clinical treatments. Finally, we calculated an ICI score for each subject to describe their tumor immune landscape and performed the risk grouping for all patients and multiomics analysis. In sum, the ICI score and clusters could be used in the future to assist clinicians in identifying patients with the greatest chance of responding to immunotherapy.

A quantitative score of immune cell infiltration predicts the prognosis in pancreatic ductal adenocarcinoma

Identification of the Immune Cell Infiltration Landscape in Pancreatic Cancer to Assist Immunotherapy.

Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

A Novel Immunogenic Cell Death-Related Genes Signature for Predicting Prognosis, Immune Landscape and Immunotherapy Effect in Hepatocellular Carcinoma.

Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma

Comprehensive Genomic Analysis of the Prognostic and Immunological Characteristics of Tertiary Lymphoid structures and CD8+ T-cells in Pancreatic Ductal Adenocarcinoma

Identification of an Immune-Related Signature for Predicting Prognosis in Patients with Pancreatic Ductal Adenocarcinoma

Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma

Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma

Prognostic Value of Immune Scores in the Microenvironment of Colorectal Cancer

Prognostic value of tumor immune cell infiltration patterns in colon adenocarcinoma based on systematic bioinformatics analysis

Identification of Immune Cell Infiltration Landscape for Predicting Prognosis of Colorectal Cancer.

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma

Contribution of Immunoscore to Survival Prediction in Pancreatic Ductal Adenocarcinoma

Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification

A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma

Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer

Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy

Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer